NOUS-PEV
Solid tumors (personalized neoantigen vaccine)
Key Facts
About Nouscom
Nouscom is a private, clinical-stage biotech company pioneering viral vector-based cancer immunotherapies. Its core technology utilizes engineered adenovirus (GAd) and Modified Vaccinia Ankara (MVA) vectors to deliver long strings of tumor neoantigens, aiming to generate potent and specific T-cell responses against cancer. The company's pipeline features two lead clinical programs: NOUS-209, an off-the-shelf vaccine for mismatch repair deficient (dMMR) tumors and Lynch syndrome, and NOUS-PEV, a personalized neoantigen vaccine. With a seasoned leadership team experienced in viral vaccine development and a platform validated in over 4,000 subjects for infectious diseases, Nouscom is positioned to advance novel treatments in the growing cancer vaccine market.
View full company profile